Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Diabetes Care. 2010 Jun;33(6):1300-3. doi: 10.2337/dc09-2260. Epub 2010 Mar 23.
To evaluate efficacy and safety of switching from twice-daily exenatide to once-daily liraglutide or of 40 weeks of continuous liraglutide therapy.
When added to oral antidiabetes drugs in a 26-week randomized trial (Liraglutide Effect and Action in Diabetes [LEAD]-6), liraglutide more effectively improved A1C, fasting plasma glucose, and the homeostasis model of beta-cell function (HOMA-B) than exenatide, with less persistent nausea and hypoglycemia. In this 14-week extension of LEAD-6, patients switched from 10 microg twice-daily exenatide to 1.8 mg once-daily liraglutide or continued liraglutide.
Switching from exenatide to liraglutide further and significantly reduced A1C (0.32%), fasting plasma glucose (0.9 mmol/l), body weight (0.9 kg), and systolic blood pressure (3.8 mmHg) with minimal minor hypoglycemia (1.30 episodes/patient-year) or nausea (3.2%). Among patients continuing liraglutide, further significant decreases in body weight (0.4 kg) and systolic blood pressure (2.2 mmHg) occurred with 0.74 episodes/patient-year of minor hypoglycemia and 1.5% experiencing nausea.
Conversion from exenatide to liraglutide is well tolerated and provides additional glycemic control and cardiometabolic benefits.
评估将每日两次的艾塞那肽转换为每日一次的利拉鲁肽或连续 40 周使用利拉鲁肽的疗效和安全性。
在一项为期 26 周的随机试验（Liraglutide Effect and Action in Diabetes [LEAD]-6）中，当添加到口服抗糖尿病药物中时，利拉鲁肽比艾塞那肽更有效地改善 A1C、空腹血糖和β细胞功能的稳态模型评估（HOMA-B），且持续性恶心和低血糖的发生率更低。在 LEAD-6 的 14 周扩展研究中，患者从每日两次 10μg 的艾塞那肽转换为每日一次 1.8mg 的利拉鲁肽或继续使用利拉鲁肽。
从艾塞那肽转换为利拉鲁肽进一步显著降低了 A1C（0.32%）、空腹血糖（0.9mmol/l）、体重（0.9kg）和收缩压（3.8mmHg），且轻微低血糖（1.30 例/患者-年）或恶心（3.2%）的发生率较低。在继续使用利拉鲁肽的患者中，体重（0.4kg）和收缩压（2.2mmHg）进一步显著下降，轻微低血糖的发生率为 0.74 例/患者-年，1.5%的患者出现恶心。
从艾塞那肽转换为利拉鲁肽耐受性良好，并提供了额外的血糖控制和代谢益处。
Zotero 插件